Ignyte Acquisition Corp. Completes Business Combination with Peak Bio Co., Ltd.; Peak Bio to List on NASDAQ
November 2, 2022
Ignyte Acquisition Corp. completed a business combination with Peak Bio Co., Ltd., resulting in the combined company operating as Peak Bio, Inc. and commencing trading on NASDAQ under the ticker symbols PKBO (common stock) and PKBOW (warrants). The transaction positions Peak Bio to access public markets and raise capital to advance its oncology and inflammatory disease therapeutics, with Hoyoung Huh as Chairman and Stephen LaMond as COO.
- Buyers
- Ignyte Acquisition Corp.
- Targets
- Peak Bio Co., Ltd.
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Invaio Sciences Acquires Peptyde Bio
December 7, 2023
Biotechnology
Invaio Sciences has acquired Peptyde Bio, a Danforth Technology Company spinout that discovers and designs antimicrobial peptides for crop protection. The deal brings Peptyde Bio’s peptide discovery platform and IP into Invaio’s AI-enabled discovery engine and biological delivery systems to accelerate nature-positive crop protection solutions.
-
Big Cypress Acquisition Corp. Completes Business Combination with SAB Biotherapeutics
October 20, 2021
Biotechnology
Big Cypress Acquisition Corp., a Nasdaq-listed special purpose acquisition company, received shareholder approval to complete a business combination with clinical-stage biopharmaceutical company SAB Biotherapeutics. Upon closing, the combined company will be named SAB Biotherapeutics, Inc. and its common stock and warrants are expected to trade on Nasdaq, providing SAB with public-market capital to advance its antibody immunotherapy platform and clinical programs.
-
INVO Bioscience Acquires NAYA Biosciences; Combined Company to Operate as NAYA Biosciences
October 14, 2024
Biotechnology
INVO Bioscience has completed a reverse-triangular merger to acquire 100% of NAYA Biosciences, and the combined company will operate as NAYA Biosciences (NASDAQ: NAYA). The combined business will continue INVO's revenue-generating fertility operations while adding NAYA's clinical-stage oncology and autoimmune therapeutics pipeline and updating management and board composition.
-
AbbVie Completes Acquisition of Nimble Therapeutics
January 23, 2025
Biotechnology
AbbVie has completed its acquisition of Nimble Therapeutics, adding Nimble's investigational oral peptide IL23R inhibitor for psoriasis and a peptide synthesis, screening and optimization platform to AbbVie's immunology pipeline. The deal is intended to strengthen AbbVie's R&D capabilities and accelerate discovery and optimization of oral peptide therapeutics.
-
BioNTech Acquires Biotheus
February 3, 2025
Biotechnology
BioNTech SE has completed the acquisition of clinical-stage biotechnology company Biotheus for $800 million in cash and ADS consideration plus up to $150 million in milestone payments. The deal gives BioNTech full global rights to BNT327 and Biotheus' antibody platform, and adds a local R&D hub and biologics manufacturing facility in China to BioNTech's network to support its oncology strategy.
-
Capitala Group and Pike Street Capital Invest $19.5M in US BioTek Laboratories
January 8, 2019
Healthcare Services
Capitala Group, alongside Pike Street Capital, provided a $19.5 million financing package (senior secured debt and equity) to US BioTek Laboratories to support the company's next phase of growth. The capital will fund expansion of US BioTek's specialty immunology and allergy testing capabilities as well as sales and marketing initiatives.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.